Mechanism of action of the tumor-specific drug
Cybrexa Therapeutics
  • Share

Cybrexa Therapeutics was founded by world-renowned physician-scientists from Yale University and serial biotech entrepreneurs. The company is developing a new class of small molecule DNA repair inhibitors that directly target cancer tumor microenvironments. To explain the inhibitors’ mechanism of action to investors and a wider audience, Cybrexa hired Visual Science to create a short 3D animation for presentations and website.

The animation presents the novel tumor-localizing peptide technology for drug delivery. In healthy human tissue with neutral pH, the drug-containing peptide is loosely associated with the cell membrane, and the drug is not released. However, because of their metabolisms, tumor cells lower the pH level around them. In the presence of low pH, the peptide forms an alpha helix and translocates across the cell membrane, releasing the drug directly into the cell cytoplasm. Thus, the drug affects only the target tumor cells without damaging healthy tissues.

The Cybrexa Therapeutics tumor-localizing DNA repair inhibitors can be combined with chemotherapy and radiotherapy, allowing higher drug doses to be delivered both safely and with enhanced efficacy.

Visual Science team developed design of package and operating manual for the device; the latter took into account all the technical properties of the device and the needs of the target consumer working in the lab. We are very impressed with the quality of work, professionalism, and the level of scientific knowledge and expertise demonstrated by Visual Science team. We are delighted to recommend Visual Science as a reliable partner in design and public communication projects for medical and biotechnological companies.
D. A. Sakharov
CEO of the SRC "BioClinicum"